The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ICER's analysis concluded that Ozempic, Wegovy, and Zepbound are cost-effective at current prices, yet Ramachandran noted the 2026 budget impact threshold is $821 million — and GLP-1s "blow way past that threshold, even at lower numbers of uptake."
- The CDC reports about 40% of Americans have obesity, meaning even modest uptake rates among eligible patients could saddle insurers with billions in new spending.
- Long-term savings from GLP-1 treatment remain unproven in existing data, according to Ramachandran — the expected downstream reductions in cardiovascular, liver, and kidney spending "do not show that" it actually produces savings.
- Clinical trial design means GLP-1s were tested against lifestyle management plus the drug, not against no treatment, so researchers argue patients need registered dietitians, gym access, and fitness support alongside medication to sustain weight loss.
- Compounded GLP-1 drugs carry serious safety risks — the FDA has issued warning letters finding websites selling unapproved or wrong ingredients, and Lin warned patients "don't always know what you're injecting in your body."
- Many patients discontinue GLP-1s within the first year due to cost, reaching a target weight, or gastrointestinal side effects, and often regain some or all of the weight afterward, undermining the case for insurer savings.
- Coverage trends are bifurcating, per Ramachandran — becoming more accessible for specific conditions like sleep apnea, diabetes, and extremely high BMI, but more restrictive for other indications.
Why it matters: With 40% of Americans potentially eligible and GLP-1s busting the $821 million budget threshold, insurers are splitting coverage by condition — pushing some patients toward FDA-warned compounded drugs whose ingredients aren't verified. The drugs pay off only if patients stay on therapy long enough for unproven downstream savings to materialize.
